2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Animal Model
PAPER

4111 Dual-antigen targeting of CRLF2-rearranged ph-like and down syndrome-associated ALL with TSLPRxCD19 CAR T cells to decrease immunotherapeutic resistance

Tommaso Balestra, PhD, Camilo Arenas Merizalde2, Shubhmita Bhatnagar, PhD3, Michael C Yarnell4, Terry Fry, MD5, Sarah Tasian, MD6
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
4 Children's Hospital of Colorado, Aurora, Colorado, United States, University of Colorado Anschutz Medical Campus and Gates Institute, Aurora, Colorado, United States
5 Children's Hospital of Colorado, Aurora, Colorado, United States, University of Colorado Anschutz Medical Campus and Gates Institute, Aurora, Colorado, United States
6 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, United States, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, United States

Background: More than 50% of Philadelphia chromosome-like B-acute lymphoblastic leukemia (Ph-like ALL) and Down syndrome-associated B-ALL (DS-ALL) harbor CRLF2 rearrangements, which result in unique cell surface overexpression of the thymic stromal lymphopoietin receptor (TSLPR) protein and constitutive activation of intracellular JAK/STAT and other kinase signaling. While CD19-targeted chimeric antigen receptor (CAR) T cell immunotherapy (CD19CART) has proven to be highly effective at inducing initial remission in children and adolescents/young adults (AYAs) with relapsed/refractory B-ALL, approximately 50% of patients subsequently relapse within two years, often with CD19 target antigen loss. As an alternative approach, we recently demonstrated potent in vitro and in vivo activity of TSLPR-targeted CAR T cells (TSLPRCART) in preclinical models of Ph-like ALL and DS-ALL that could be further augmented by sequential co-therapy with the JAK inhibitor ruxolitinib (Balestra Leukemia 2025). In the present studies, we hypothesized that bispecific TSLPRxCD19CART immunotherapy will be more effective against CRLF2-rearranged Ph-like and DS-ALL and/or decrease risk of antigen-loss relapse ultimately in patients, similar to recent CD19 and CD22 CAR T cell co-targeting approaches for patients with relapsed/refractory B-ALL under early phase clinical investigation by our group (NCT05674175) and others.

Methods: A second-generation bicistronic TSLPRxCD19 co-targeted CAR T cell construct with 4-1BB/CD3z costimulatory domains was designed using our established methods (Niswander Haematologica 2023). In vitro CAR T cell functionality was measured by co-incubation with human ALL cells, as well as cell viability by luciferase assays or flow cytometry and IFN-g production by ELISA. In vivo activity of bispecific and monovalent CAR T cells was assessed in patient-derived xenograft (PDX) murine models.  ALL cells and CAR T cells were measured by quantitative flow cytometry analysis of weekly retro-orbital venous blood and end-study spleens. IFN-γ measurements and multiplex cytokine secretome analyses using Isoplexis technology were performed on serially-collected murine plasma samples.

Results:  TSLPRxCD19CART induced potent in vitro and in vivo anti-leukemia activity against the TSLPR+/ CD19+ MUTZ5 ALL cell line with comparable effects to those of monovalent TSLPRCART or CD19CART. Robust in vivo inhibition of leukemia progression was also observed in TSLPR+/CD19+ CRLF2-R Ph-like ALL PDX models (n=2) with detected T cell expansion and IFN-γ production comparable to that of monospecific CD19CART and TSLPRCART. Importantly, TSLPRxCD19CART was also effective in vivo against engineered TSLPR+/CD19- MUTZ5 ALL cells and an endogenously TSLPR-/CD19+ ALL PDX model, emphasizing the ability of ‘OR-gated’ bispecific construct-transduced T cells to kill leukemia with only one of two target antigens that may be relevant in the clinic for patients with relapsed CRLF2-rearranged ALL and CD19 antigen loss. Isoplexis analysis of plasma samples from CART-treated ALL PDX mice suggested similar functionality of the TSLPRxCD19CART product compared to TSLPRCART or CD19CART given analogous T cell-induced cytokine (n=20) production including  elevated levels of IFN-γ and perforin. Analysis of T cell activation markers identified no significant differences between TSLPRxCD19CART versus TSLPRCART or CD19CART after in vitro stimulation with MUTZ5 cells.

Discussion: Our data show that TSLPRxCD19CART has potent anti-leukemia activity against CRLF2-rearranged Ph-like ALL compared to single antigen-targeted TSLPRCART or CD19CART. Additional studies are now assessing the potential differential toxicity and therapeutic efficacy of TSLPRxCD19CART in DS-ALL PDX models and additional Ph-like ALL models. Adjacent to these studies and based upon our prior preclinical work (Qin Blood 2015), a first-in-human phase 1 clinical trial of monospecific TSLPRCART immunotherapy for children and adults with relapsed TSLPR+ leukemias is in development. If initial safety data are demonstrated from this trial targeting TSLPR as a novel antigen, we aim to translate results of our preclinical studies to a successor first-in-human phase 1 trial of TSLPRxCD19CART immunotherapy with a goal of improving long-term remission rates and/or mitigating antigen loss relapse risk in children and AYAs with CRLF2-rearranged Ph-like or DS-ALL.
Tommaso Balestra, PhD: No relevant conflicts of interest to declare.